Back
ESCO Technologies 10K Form
Sell
32
ESE
ESCO Technologies
Last Price:
$135.23
Seasonality Move:
9.12%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-10 | 10Q | ESE/ESCO Technologies Quarterly |
2024-02-09 | 10Q | ESE/ESCO Technologies Quarterly |
2023-08-09 | 10Q | ESE/ESCO Technologies Quarterly |
2023-05-10 | 10Q | ESE/ESCO Technologies Quarterly |
2023-02-09 | 10Q | ESE/ESCO Technologies Quarterly |
2022-08-09 | 10Q | ESE/ESCO Technologies Quarterly |
Receive ESE News And Ratings
See the #1 stock for the next 7 days that we like better than ESE
ESE Financial Statistics
Sales & Book Value
Annual Sales: | $1B |
---|---|
Cash Flow: | $57.3M |
Price / Cash Flow: | 44.15 |
Annual Sales: | $48.05 |
Price / Book: | 2.82 |
Profitability
EPS (TTM): | 3.94000 |
---|---|
Net Income (TTM): | $101.9M |
Gross Margin: | $404M |
Return on Equity: | 8.66% |
Return on Assets: | 5.73% |
ESCO Technologies Earnings Forecast
Key ESCO Technologies Financial Ratios
-
The Gross Profit Margin over the past 35 years for ESE is 39.35%.
-
The Selling, General & Administrative Expenses for ESE have been equal to 21.82% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 14.97% of Operating Income.
-
The Net Earning history of ESE is 9.92% of Total Revenues.
-
Per Share Earnings over the last 35 years have been positive in 21 years.
ESCO Technologies Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Machinery |
Sector: | Industrials |
Current Symbol: | ESE |
CUSIP: | 296315 |
Website: | escotechnologies.com |
Debt
Debt-to-Equity Ratio: | 0.1 |
---|---|
Current Ratio: | 1.91 |
Quick Ratio: | 1.25 |
Price-to-Earnings
Trailing P/E Ratio: | 34.34 |
---|---|
Forward P/E Ratio: | 24.48 |
ESE Technical Analysis vs Fundamental Analysis
Sell
32
ESCO Technologies (ESE)
is a Sell
Is ESCO Technologies a Buy or a Sell?
-
ESCO Technologies stock is rated a SellThe current ESCO Technologies [ESE] share price is $135.31. The Score for ESE is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.